Immune Suppression by Dermal Exposure to JP-8 Jet Fuel
Abstract
During the next funding period we intend to address four major questions. 1) How does JP-8 induce immune suppression? Does JP-8 alter immune responsiveness through its effect on cytokine production or does it alter the ability of antigen presenting cells to present antigen? 2) Does JP-8 exposure affect ongoing immune reactions? Will exposure to JP-8 interfere with the immune response to recall antigens and block the protective effect of prior immunization? 3) How can we prevent JP-8 induced immune suppression? Once a better understanding of the suppressive mechanism is obtained, we will begin to design rational steps aimed at preventing its immune suppressive effect. 4) What components in JP-8 induce dermal immunotoxicity? JP-is produced from commercial Jet-A by use of an additive package containing diethylene glycol monomethyl ether, (DiEGME) an anti-icing compound. Because some have suggested DiEGME is a dermal immunotoxin we will concentrate on determining if application of DiEGME induces immune suppression. The specific aims of this proposal are designed to gain an understanding of the mechanism(s) involved in JP-8-induced immune suppression. The long-term of this work is to use the knowledge obtained here to design a procedure to prevent JP-8-induced immune suppression and limit its potential harmful effect on USAF personnel.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 18, 2005
- Accession Number
- ADA437910
Entities
People
- Stephen E. Ullrich
Organizations
- McGovern Medical School